In Brief
Dendritic cells can be divided into multiple functional subsets. Chopin et al. show that the transcription factor PU.1 promotes development of conventional dendritic cells while suppressing plasmacytoid dendritic cell formation. PU.1 functions by activating the expression of DC-SCRIPT, a key regulator of conventional dendritic cell differentiation.
INTRODUCTION
Dendritic cells (DCs) are a ubiquitous but heterogeneous population of hematopoietic cells. DCs are sentinels that capture antigens, sense pathogens (especially infectious ones) through the expression of pattern-recognition receptors, and initiate T-cell-adaptive immunity. Often described as professional antigen-presenting cells, DCs orchestrate both tolerance induction and protective immunity.
Steady-state DCs are categorized into two major lineages, plasmacytoid DCs (pDCs) and conventional DCs (cDCs) (Guilliams et al., 2014) . Although the exact origins of the DC lineages remain a subject of current research Naik et al., 2013; Rodrigues et al., 2018) , there is experimental evidence that at least some pDCs and cDCs arise from a common DC progenitor (CDP) in the bone marrow (BM) (Naik et al., 2007; Onai et al., 2007) . Whereas pDCs fully mature in the BM and are characterized by their ability to produce large amounts of type I interferon (IFN) early during viral infection, cDCs leave the BM in a pre-committed stage and, upon seeding peripheral organs, mature into two phenotypically and functionally distinct subsets: cDC1s (including the formerly described CD8 + and CD103 + DCs) and cDC2s (formerly identified as CD11b + CD172a + DCs) (Guilliams et al., 2014) . Whereas pDC differentiation and identity rely on the transcription factor E2-2 (Cisse et al., 2008; Ghosh et al., 2010) , no transcription factor has been ascribed for cDC identity (required for all cDCs, but not for pDCs). The transcription factor Zbtb46 represents a candidate for such a regulator because it is expresses relatively specifically in cDCs. However, Zbtb46 is largely dispensable for cDC development (Meredith et al., 2012a; Meredith et al., 2012b; Satpathy et al., 2012) . The molecular processes controlling further cDC diversification have been extensively studied (Belz and Nutt, 2012; Chopin et al., 2012; Murphy et al., 2016) . cDC1 differentiation is controlled by transcription factors BATF3 (Hildner et al., 2008) , IRF8 (Hambleton et al., 2011; Schiavoni et al., 2002) , NFIL3 (Kashiwada et al., 2011) , and ID2 (Hacker et al., 2003) . cDC2 differentiation is less understood but is dependent on NOTCH2 (Satpathy et al., 2013) , IRF4 (Gao et al., 2013; Persson et al., 2013; Schlitzer et al., 2013) , and KLF4 (Tussiwand et al., 2015) .
The Ets-family protein PU.1, encoded by Spi1, is one of the broadest-acting hematopoietic transcription factors and coordinates many aspects of lymphoid and myeloid cell development. Increased PU.1 concentration, either through endogenous mechanisms (Kueh et al., 2013; Laslo et al., 2006) or through ectopic expression (DeKoter and Singh, 2000; Laiosa et al., 2006) , can direct stem and lymphoid progenitor cells toward a myeloid fate, yet the molecular mechanisms by which PU.1 promotes appropriate lineage specification has remained unclear. PU.1 is required for the development of all DCs and Langerhans cells from hematopoietic progenitors (Carotta et al., 2010; Chopin et al., 2013) , and loss of a single Spi1 allele impedes the differentiation of cDCs, but not pDCs. Thus, PU.1 is an attractive candidate for a dose-dependent regulator of the cDC lineage determination.
To unmask the role of this complex transcription factor in the diversification of the DC lineages, we conditionally inactivated PU.1 in lineage-committed DCs. Ablation of PU.1 in CD11c-expressing cells skewed the DC differentiation program by increasing pDCs at the expense of cDCs. PU.1 promoted DC functions, such as antigen presentation and cytokine secretion, as well as cDC identity through the direct activation of the transcriptional regulator DC-SCRIPT (encoded by Zfp366). DC-SCRIPT was in turn required for the differentiation program of cDC1s, thus highlighting a PU.1 and DC-SCRIPT node in DC diversification.
RESULTS

Loss of PU.1 Alters the Ratio of cDC to pDC Differentiation In Vivo
We had previously reported that commitment of a CDP into the pDC lineage coincides with a sharp reduction of PU.1 expression, measured by a Spi1 GFP reporter strain (Carotta et al., 2010; Nutt et al., 2005) . We re-analyzed the cDC compartment and found a hitherto unappreciated increase in PU.1 expression upon commitment of the CDP into the cDC lineages (Figures S1A-S1C). Consequently, we speculated that changes in PU.1 concentration might be a key event driving pDC and cDC differentiation.
To investigate the specific function of PU.1 within committed DCs, we made use of the Spi1 fl/fl Itgax cre mouse strain, hereafter named PU.1cKO, which conditionally inactivates PU.1 in all CD11c + DCs. The Itgax cre strain mediates efficient deletion of floxed alleles in splenic cDCs and pDCs while showing only partial activity in BM DCs (Caton et al., 2007; Ghosh et al., 2010) . In keeping with this, intracellular staining for PU.1 in splenic cDCs and pDCs revealed a sharp reduction in the concentration of PU.1 observed in DCs isolated from PU.1cKO mice; as expected, this resulted in decreased CD135 (FLT3) expression (Figures S1D and S1E) . Consistent with their lack of CD11c expression, CDP numbers were unaffected by PU.1 loss (Figure 1A) . In contrast, the absolute numbers of cDC1s and cDC2s were significantly reduced in the spleens of PU.1cKO mice ( Figure 1B) . The remaining PU.1cKO cDCs had an abnormal phenotype with reduced cell-surface expression of lineage-defining markers such as Clec9A, XCR1, CD103, and CD8 on cDC1s and CD11b, CD172a, and CD4 on cDC2s ( Figures 1B and 1C ). In the gut and mesenteric lymph node (LN) of PU.1cKO mice, the composition of DC subsets was altered, and there was a reduced frequency of CD103 + DCs (Satpathy et al., 2013) . Infection of PU.1cKO mice with C. rodentium led to significant colitis (measured by colon shortening) and impaired immune protection (measured by bacterial dissemination to the spleen) ( Figures S2C and S2D ), thus confirming the reduced functionality of CD11b + CD103 + DCs in the PU.1cKO gut. These results highlight the critical role of PU.1 in controlling cDC homeostasis in multiple anatomical sites.
Loss of PU.1 Alters the Ratio of cDC to pDC Differentiation
In contrast to the loss of cDCs, we observed an increased number of pDCs in the BM and spleen of PU.1cKO mice (Figures 1D and 1E) , suggesting that PU.1 represses pDC formation. To test this possibility, we performed a limiting dilution assay whereby a defined number of CDPs or common lymphoid progenitors (CLPs), isolated either from WT or from PU.1cKO BM, were cultured with Flt3L-preconditioned CDPs from C57BL/6-Ly5.1 congenic mice. After 7 days, cells were harvested and the differentiation potential of the WT or PU.1cKO progenitors (both Ly5.2 + ) was assessed by flow cytometry. In concordance with the literature (Naik et al., 2007) , WT CDPs differentiated into cDC1s, cDC2s, and pDCs, the last of which were the least abundant at this time point (Figure 2A ). In contrast, PU.1cKO CDPs displayed a limited capacity to differentiate into cDCs and a clear bias for generating pDCs (Figure 2A ), whereas WT and PU.1cKO CLPs gave rise almost exclusively to pDCs ( Figure 2B ). These experiments show that PU.1 is essential in promoting the differentiation of cDCs and that loss of PU.1 in DC progenitors favors pDC differentiation.
PU.1 Controls cDC Identity
To better understand the role of PU.1 in balancing cDC and pDC differentiation and to establish its role in controlling DC functions, we performed RNA sequencing (RNA-seq) of purified WT and PU.1cKO splenic cDCs and pDCs. Because of the aberrant expression of key lineage markers in the PU.1cKO mice, cDC1s and cDC2s were not examined in isolation. To prioritize the most important differences, we restricted our analysis to genes showing a >1.8-fold change and a false-discovery rate (FDR) < 0.05 in this and all subsequent analyses. By this criterion, comparison of WT cDCs and pDCs revealed that 1,508 genes were increased in pDC, whereas 1,854 were increased in the cDC lineage ( Figure 3A and Table S1 ). Comparison with a previous pDC signature derived by microarray profiling (Sawai et al., 2013) suggested that our dataset provides a useful resource for further analysis of the cDC and pDC commitment process ( Figure 3B ). To assess the molecular functions of PU.1 in DCs, we compared RNA-seq data on cDCs and pDCs isolated from WT or PU.1cKO mice. CD11c-driven Spi1 inactivation mediated by Cre recombinase was confirmed to be efficient and result in a reduction in transcripts coding for the floxed exon 5 in both PU.1cKO cDCs and pDCs ( Figures 3C). Comparison of the data from WT and PU.1cKO cDCs identified 767 cDC genes activated by PU.1 and 760 cDC genes repressed by PU.1 ( Figure 3D and Table S2 ). Gene pathway analysis using the metascape platform for the genes that are positively regulated by PU.1 highlighted its role in controlling genes encoding cytokines (Il12b, Il27, and Il18) and genes involved in cell adhesion and migration processes (Itgax, Itga6, Itga3, Rab30 , and Rab43) ( Figure S3A and Table S4 ).
To determine whether PU.1 is a key determinant of cDC identity, we asked how many of the 1,854 cDC genes ( Figure 3A) were positively regulated by PU.1 (enriched in WT cDCs) or negatively regulated by PU.1 (enriched in PU.1cKO cDCs). We found that 501 of the 767 PU.1-activated genes, representing 27% of the cDC-specific genes, were components of the cDC signature. (Figure 3E and Table S3 ). To define PU.1-regulated genes in cDC1s and cDC2s, we utilized the Immgen database to categorize these 501 genes positively controlled by PU.1 in cDCs according to their expression profile in cDC1s and cDC2s (Miller et al., 2012) . PU.1 regulated approximately 20% of the genes associated with either the cDC1 or cDC2 gene signatures ( Figures S3B and S3C ). PU.1-dependent cDC genes included Figure 1A ) from WT and PU.1cKO BM (both Ly5.2 + ), and the indicated number was added to a culture of congenic C57BL/ The y axis shows log 2 fold change, and the x axis shows average log 2 counts per million. Genes with significantly increased (pDC genes, red) or decreased (cDC genes, blue) expression are highlighted (TREAT FDR < 0.05 relative to 1.8-fold-change threshold).
(B) Barcode enrichment plot showing the correlation of a previously reported pDC signature gene set (Sawai et al., 2013) with the RNA-seq results shown in (A). Genes are ordered on the plot from right to left from most upregulated to most downregulated in pDCs versus cDCs according to the moderated t-statistic (x axis).
Signature genes from Sawai et al. (2013) (legend continued on next page) transcription factors Zbtb46, Ciita, Egr1, and Zfp366; members of the Ras superfamily of monomeric G proteins Rab30 and Rab43; and the chemokine receptor Xcr1 ( Figure 3E and Table S3) . Notably, the expression of the cDC-lineage-specific transcription factors Irf8, Id2, Irf4, Klf4, and Batf3 was equivalent between the WT and PU.1cKO cDCs, implying that PU.1 function in cDCs is largely independent of these established regulators ( Figure S3D ). In contrast to the high proportion of PU.1-activated genes within the cDC signature, only 111 of the 760 PU.1-repressed genes were enriched in cDCs, representing 6% of the cDC gene signature. Altogether, these analyses reveal that PU.1 plays an essential role in promoting cDC gene expression.
PU.1 Represses pDC Gene Expression
Analysis of the consequence of PU.1 inactivation in pDCs revealed that 361 genes were de-repressed, whereas 483 genes required PU.1 for their expression ( Figure 3F and Table S5 ). In contrast to the cDC compartment, where PU.1 played a critical role in controlling cDC signature genes, only 158 of the 483 genes positively regulated genes by PU.1 in pDCs were found to be in the 1,508-gene pDC signature (10.5%). Similarly, only 24 of the 361 genes negatively regulated by PU.1 in pDCs belonged to the pDC signature (1.6%). These observations indicate that PU.1 is largely dispensable for the establishment of the pDC transcriptome. These results suggest that maintaining the high expression of PU.1 in DC progenitors promotes the cDC gene expression program at the expense of pDC differentiation. In support of this hypothesis, we found that several transcription factors positively associated with cDC commitment, including Ciita, Ehf, Atf3, and Egr1 (Miller et al., 2012; Pandey et al., 2013) , were downregulated in PU.1cKO cDCs. These data also revealed that several genes normally downregulated upon cDC commitment and associated with pDC differentiation (including the genes encoding transcription factors E2-2 [Tcf4] and RUNX2 and cell-surface proteins Ly6C2 and CD62L) were upregulated upon PU.1 ablation in cDCs ( Figures 3G-3I ). The de-repression of pDC genes in PU.1-deficient cDCs was not restricted to these individual examples. Gene-set enrichment analysis revealed that genes constituting the pDC gene signature were predominately upregulated in PU.1cKO cDCs ( Figure 3J ). Thus, PU.1 actively maintains cDC cell fate while at the same time repressing pDC-specific gene expression.
PU.1 Marks Distinct Genomic Regions in cDCs and pDCs
To better define the mechanism by which PU.1 controls DC fate and function, we performed chromatin immunoprecipitation sequencing (ChIP-seq) of PU.1 from purified cDCs and pDCs isolated from Flt3L cultures. In concordance with an earlier report (Lin et al., 2015) , PU.1 bound widely to the genome of cDCs and pDCs. Analysis of PU.1 binding regions, even with a rigorous threshold (FDR < 0.05), detected more than 60,000 PU.1 binding sites in cDCs and more than 55,000 in pDCs (Figure S4A) . Despite substantial overlap between the lineages, comparison of the binding profiles between the cDC and pDC subsets detected over 17,000 regions that were bound more strongly in cDCs and 1,700 where binding was increased in pDCs ( Figure S4A ; FDR < 0.05). PU.1 binding in the gene-promoter regions and sequences surrounding a transcription start site (TSS) (À3 kb > TSS < +1 kb) accounted for 17.4% and 19% of the regions bound by PU.1 in cDCs and pDCs, respectively. Intragenic binding was frequent in both subsets, accounting for 50% of the total number of PU.1 binding sites observed. The remaining binding was distal (>5 kb) to a gene body and represented over 30% of the detected PU.1 bound regions (Figure S4B) . This pervasive binding suggests that PU.1 plays an instructive role in marking specific genomic regions in DC subsets and thus allows the recruitment of secondary determinants that drive lineage-specific genes, a conclusion consistent with the view that PU.1 is important for enhancer organization (Ghisletti et al., 2010; Heinz et al., 2010) . To test this possibility, we focused our analysis on the sequences in the direct vicinity of PU.1-differentially-bound regions (±500 bp) in cDCs and pDCs and asked whether there was significant enrichment of known transcription binding motifs. We found that regions containing cDC-specific PU.1 binding were significantly enriched with motifs recognized by the transcription factors BATF-JUN, ETS, and MAF-B, whereas pDC-specific PU.1 binding regions were enriched with motifs recognized by E-box, RUNX, or FOXO (Figure S4C) . Thus, PU.1 marks distinct genomic regions in cDCs and pDCs that are enriched with transcription factor motifs known to bind DC-lineage determinants.
PU.1 Controls Cardinal DC Functions
Our analysis revealed that PU.1 directly controls the expression of key genes associated with the ability of DCs to cross-present antigens (Rab43) , support T cell proliferation (Il12b), and produce co-activation signals (Cd86) ( Figure 4A ). To test whether PU.1 loss affects antigen presentation by DCs, we assessed the capacity of PU.1cKO cDC1-and cDC2-like cells to present antigens directly (via MHCII) or through cross-presentation (via MHCI) to transgenic T cells in vivo. Labeled MHCIand MHCII-restricted ovalbumin (OVA)-specific T cells (OT-I and OT-II, respectively) were adoptively co-transferred into WT (F) MD plot of differential gene expression in PU.1cKO versus WT pDCs. Genes with significantly increased (PU.1-repressed genes, red) or decreased (PU.1-activated genes, blue) expression upon PU.1 deletion in pDCs are highlighted. Differential expression was defined as in (A). (G) Heatmap (left) and bar plots (right) showing differential gene expression upon PU.1 inactivation in cDCs. Only transcription factors that have been identified as positively or negatively associated with cDC commitment and differentially expressed upon PU.1 ablation in cDCs are shown (Miller et al., 2012) . The heatmap shows log expression standardized by row. Bar plots show RPKM (reads per kilobase of transcript per million reads mapped) for selected differentially expressed genes in WT (red) and PU.1cKO (gray) cDCs. Genes are ordered from right to left from most upregulated to most downregulated in PU.1cKO versus WT cDCs (p = 3.4eÀ6 using Limma's FRY function). Data in all panels, except (I), are from two independent samples per genotype. Please also see Figures S3 and S4 and Tables S1-S5. and PU.1cKO mice. After OVA immunization, we observed that the proliferation of both OT-I and OT-II was substantially reduced in PU.1cKO compared with WT hosts, suggesting that antigen presentation via either route was diminished without PU.1 (Figure 4B) . Because the reduced number of cDCs present in PU.1cKO mice could account for the decreased T cell proliferation, we turned to an in vitro antigen-presentation assay where cDC numbers can be equilibrated between the genotypes. Similar to the in vivo findings, the lack of PU.1 greatly affected the capacity of DCs to stimulate either OT-I or OT-II cells in vitro ( Figure 4C ). We also noted that cDC1s and cDC2s isolated from PU.1cKO mice had a decreased capacity to upregulate the co-stimulatory molecules CD80, CD86, and CD40 when they were stimulated with either OVA (Figure 4D ) or lipopolysaccharide (data not shown). In these cultures, we observed a substantial drop in cDC1 and cDC2 survival in the absence of further stimulation in both WT and PU.1cKO cDCs, the latter of which were more susceptible to death in the absence of a stimulus (Figure 4E ). Exposure to OVA increased the survival of cDCs of both genotypes, but again the PU.1cKO cDCs were significantly less viable than WT DCs ( Figure 4E ). These observations suggest that PU.1 might play a role in the survival of mature cDCs. The BCL-2 family of proteins includes well-characterized apoptosis regulators that can be classified into three groups: pro-apoptotic BH3-only inhibitors, pro-apoptotic effectors, and anti-apoptotic guardians. Only the transcripts found in the latter group were affected by PU.1 ablation in cDCs. Bcl2 expression increased in PU.1cKO cDCs, whereas Mcl1 and Bcl2a1a (encoding A1), both of which regulate cDC homeostasis (Carrington et al., 2015; Schenk et al., 2017) , required PU.1 for their full expression ( Figure 4F ). These data demonstrate the functional impairment of PU.1-deficient cDCs, which can be explained by decreased survival and impaired capacity to express several key molecules associated with antigen presentation and the stimulation of T cell proliferation.
Compared with cDCs, pDCs have reduced antigen-presentation capacity and are instead tuned to sense virus-derived nucleic acids through the expression of the Toll-like receptors (TLRs) 7 and 9 and respond through the rapid production of type I IFN. To test whether PU.1 loss affects their response to TLR ligands, we purified pDCs from WT and PU.1cKO spleens and stimulated them for 18 hr with CpG, a TLR9 agonist. Both WT and PU.1cKO pDCs increased the expression of MHCII upon CpG stimulation, indicating that both had been sensed and activated by CpG ( Figure 4G) . However, the concentration of IFN-a found in the supernatants of activated pDCs was significantly reduced in the absence of PU.1, indicating that PU.1 is required for an optimal IFN-a response by pDCs ( Figure 4H ). This PU.1 is essential for the immunological functions of both cDC and pDCs.
Zfp366 (DC-SCRIPT) Is a Direct PU.1 Target Gene in cDCs As mentioned above, none of the genes encoding the known cDC lineage determinants required PU.1 for their expression, and thus alteration in their activity cannot contribute to the impaired cDC differentiation observed in PU.1cKO mice (Figure S3D) . Therefore, we sought to identify other factors that could explain the skewed cDC:pDC ratio observed in PU.1cKO mice. To restrict our search, we hypothesized that the factor(s) involved should fulfill the following criteria: (1) it must be expressed in cDCs and constitute a cDC signature gene (Table  S1 ), (2) PU.1 must bind in the locus of the factor in cDCs, but not pDCs (Table S6) , and (3) expression of the factor must be significantly perturbed by the loss of PU.1 in cDCs (Table S2) . Mining our dataset revealed 129 genes fulfilling these criteria ( Figure 5A) .
Among the 129 genes were two transcription factors that represented excellent candidates for further consideration, Zbtb46 and Zfp366. Zbtb46 expression defines the cDC lineage, whereas its activity in DC progenitors appears to restrict granulocyte potential by repressing key genes involved in this process (Meredith et al., 2012a; Satpathy et al., 2012) . However, DC differentiation occurs normally in Zbtb46 À/À mice, suggesting that downregulation of this gene alone cannot explain the disturbed DC differentiation observed in the absence of PU.1. The second candidate, Zfp366, encodes DC-SCRIPT, a poorly understood Zn-finger transcription factor (Hontelez et al., 2013; Triantis et al., 2006a; Triantis et al., 2006b ) whose expression in mature immune cells is largely restricted to the cDC lineage ( Figures  5B and S5 ). Zfp366 expression is absent from all BM progenitors ( Figure S5 ) and CDPs before being initially upregulated in precDC1s and to its maximal level in mature cDC1s (Grajales-Reyes et al., 2015; Schlitzer et al., 2015) . Zfp366 expression was specifically regulated by PU.1 in cDCs ( Figures 5C-5E ). We then confirmed the absence of DC-SCRIPT at the protein level in both cDC1s and cDC2s isolated from PU.1cKO mice ( Figure 5E ). Figure 5F ). Collectively, these observations highlight Zfp366 as a direct PU.1 target gene in cDCs.
DC-SCRIPT Promotes cDC Differentiation
To investigate the role of DC-SCRIPT in DC differentiation, we transduced WT BM progenitors with either an empty-vector control or a DC-SCRIPT-encoding retrovirus, both of which also expressed GFP, and then cultured them in Flt3L. In the control cells, untransduced (GFP À ) or transduced (GFP + ) progenitors possessed the same ability to differentiate into pDCs ( Figure 6A ). In contrast, DC-SCRIPT-transduced progenitors displayed greatly reduced pDC differentiation potential, as assessed by cell-surface markers ( Figure 6A ) and Tcf4 expression ( Figure 6B ). To analyze the consequences of DC-SCRIPT overexpression on cDC differentiation, we assessed the phenotype of transduced cDCs by flow cytometry. Overexpression of DC-SCRIPT increased the frequency of the cDC1 population, defined as either CD24 + CD172a low ( Figure 6C ) or CD11b low XCR1 + (Dorner et al., 2009 ), in comparison with cDC2s ( Figure 6D ). This programming was independent of the induction of the cDC1-defining transcription factors NFIL3, BATF3, and ID2 because their transcripts were not altered by enforced DC-SCRIPT expression. This contrasts with the cDC1 marker XCR1, whose transcripts were positively regulated by DC-SCRIPT ( Figure 6E ). Thus, enforced expression of DC-SCRIPT promotes cDC1 differentiation at the expense of cDC2s and pDCs.
DC-SCRIPT Overexpression Restores the cDC:pDC Ratio in the Absence of PU.1
The above findings suggest that PU.1 and DC-SCRIPT might cooperatively control cDC differentiation and repress pDC formation. To test this hypothesis, we used a gain-of-function approach to overexpress PU.1 or DC-SCRIPT in WT and PU.1cKO BM-derived DCs. As expected, PU.1cKO BM progenitors transduced with the empty-vector control displayed a greater potential to generate pDCs than WT cells ( Figure S6 ).
However, upon overexpression of either PU.1 or DC-SCRIPT, PU.1cKO progenitors regained their capacity to generate pDC and cDC proportions similar to those of WT progenitors. Consistent with our observations, PU.1 and DC-SCRIPT overexpression in WT progenitors led to increased cDC differentiation ( Figure S6 ).
DC-SCRIPT Balances cDC versus pDC Development
To further substantiate the role of DC-SCRIPT in controlling DC lineage specification in a loss-of-function setting, we used CRISPR/Cas9-mediated genome editing to disrupt DC-SCRIPT expression in DCs. A lentivirus expressing a small guide RNA (sgZfp366-ires-mCherry) to the first exon of Zfp366 was introduced into BM progenitors isolated from Cas9Tg GFP mice (Chu et al., 2016) , and these cells were cultured for a further 7 days in Flt3L. The introduction of sgZfp366 very efficiently disrupted DC-SCRIPT expression in DCs ( Figure 7A ). Phenotype analysis revealed that the loss of DC-SCRIPT significantly increased the ratio of pDCs to cDCs generated by sgZfp366-transduced DCs compared with control cells (Figure 7B ). cDC1s were most Figure 3D ), the cDC signature genes (cDC genes, as in Figure 3A) , and the PU.1 differentially bound genes (DB genes, as in Figure S4A ). The identity of some of the 129 genes in the overlap of the groups is listed to the right. sensitive to DC-SCRIPT loss, as indicated by the substantial reduction in CD24 + or XCR1 + cDC1s in transduced cells (Figure 7C ). This finding confirms that DC-SCRIPT promotes cDC formation at the expense of the pDC pathway.
To assess the consequences of DC-SCRIPT ablation in vivo, we isolated BM progenitors from Cas9Tg GFP and Ly5.1 (competitor-Cas9 À cells) mice and transduced them with a lentivirus expressing either sgZfp366 or a guide RNA targeting Irf8 as a positive control (sgIrf8). The next day, transduced cells were adoptively transferred into sub-lethally irradiated recipients, and the capacity of the transduced cells to differentiate into DCs was analyzed 5 weeks later ( Figure 7D ). As expected, interference with Irf8 expression in progenitors crippled cDC differentiation in vivo ( Figures 7D and 7E ) and in vitro after culture of the progenitors from the chimeric mice in Flt3L (Figures S7A-S7C ).
In contrast, DC-SCRIPT loss did not impede cDC2 differentiation but rather decreased cDC1 potential and increased the capacity of progenitors to differentiate into pDCs in vivo and in vitro Please also see Figure S7 .
( Figures 7G, 7H , S7D, and S7E). Together, these data confirm that DC-SCRIPT prevents pDC differentiation while promoting cDC1 development.
DISCUSSION
The transcription factor PU.1 controls many aspects of hematopoiesis in a dose-dependent manner, although how changes in PU.1 concentration lead to altered cell-fate decisions on a molecular scale remains poorly understood (DeKoter and Singh, 2000; Kueh et al., 2013; Laiosa et al., 2006; Laslo et al., 2006) . The process by which progenitors commit to either the pDC or cDC pathway represents an excellent situation for investigating this process because commitment into the pDC lineage leads to a sharp reduction of PU.1, whereas its expression remains high in cDCs . Consistent with the high level of PU.1 in all multipotent progenitors, including CDPs, PU.1 inactivation at these early stages of development is detrimental for the generation of all DC types (Carotta et al., 2010) . This severe early-developmental block, however, precluded us from addressing two important questions: (1) is the reduced concentration of PU.1 a driver of pDC cell fate, and (2) what is the role of PU.1 in mature cDCs and pDCs? In this study, we used a model of conditional inactivation of PU.1 in DC-restricted progenitors to address these questions.
To decipher the distinct functions of PU.1 in the pDC and cDC commitment process, we examined the DNA binding activity of PU.1 in both cell types. PU.1 is often described as a pioneer factor because it allows chromatin accessibility to secondary determinants driving lineage-specific gene expression (Heinz et al., 2010) . In keeping with this idea, we found that cDC-specific and pDC-specific PU.1-bound regions were often enriched with motifs known to be recognized by cDC-or pDC-lineagedetermining transcription factors, respectively. For example, pDC-specific PU.1-bound regions were enriched with motifs recognized by the E2-2 and RUNX families of transcription factors, which agrees with our previous finding that the association of PU.1 and RUNX2 was necessary to drive high IRF7 expression and thus type-I IFN production in pDCs (Chopin et al., 2016) . In support of this hypothesis, the absence of PU.1 in pDCs reduced IRF7 expression in pDCs, but not in cDCs that lacked RUNX2. Examples such as this suggest an instructive role for PU.1 whereby its binding to DNA marks specific genomic regions to render them permissive to regulation by other lineage-restricted transcription factors.
Although the origins of cDCs and pDCs remain a subject of active investigation Naik et al., 2013; Rodrigues et al., 2018; Schlitzer et al., 2015) , at least some CDPs can develop into both cDCs and pDCs (Naik et al., 2007; Onai et al., 2007) . In this study, we have provided evidence that high PU.1 expression is a driving force in promoting cDC commitment. Loss of PU.1 in DC-restricted precursors resulted in significantly increased pDC differentiation. Furthermore, PU.1-deficient cDCs showed a striking de-repression of the genes that normally define the pDC lineage. These findings show that PU.1 is a negative regulator of the pDC lineage, highlighting PU.1 downregulation as a defining moment in pDC lineage commitment. Given that members of the E protein family, including E2-2, are essential regulators of lymphocyte development, it has been proposed that E protein action might account for the lymphoid-like features displayed by pDCs (Reizis, 2010) . In agreement with this concept, expression of PU.1 in pDCs closely matches that observed in B cells (Chopin et al., 2016; Nutt et al., 2005) , suggesting that this relatively lower concentration of PU.1 is also involved in shaping this aspect of the pDC transcriptome. In contrast, high PU.1 concentration is an essential instructor of myelopoiesis (DeKoter and Singh, 2000; Kueh et al., 2013) , and thus we propose that its continuous high expression in cDCs not only prevents the activation of the pDC lineage program in DC progenitors but also promotes cDC differentiation and function.
PU.1 most likely maintains cDC fate through multiple mechanisms, given that it positively controls 27% of the cDC gene signature. Despite the clear binding by PU.1, the expression of all the transcription factors known to be involved in cDC differentiation was normal in the absence of PU.1. In contrast, we identified DC-SCRIPT as a key determinant in cDC1 commitment. DC-SCRIPT is a transcriptional repressor whose hematopoietic expression is restricted to the myeloid compartment (Triantis et al., 2006a; Triantis et al., 2006b ). In DC ontogeny, Zfp366 expression is absent from CDPs and pDCs but is rapidly upregulated in developing cDCs and reaches its peak expression in mature cDC1s (Grajales-Reyes et al., 2015; Schlitzer et al., 2015) . Consistent with our conclusion, previous studies using knockdown of DC-SCRIPT in monocyte-derived DCs have highlighted a role for DC-SCRIPT in regulating IL-12 expression and the magnitude of the resulting T cell responses (Hontelez et al., 2013) , functions that were also impaired in cDCs lacking PU.1.
In summary, our study highlights the critical role for PU.1 in promoting differentiation down the cDC lineage trajectory through the control of DC-SCRIPT while actively repressing the pDC gene expression program. These findings uncover a regulatory node that directs DC progenitors into the cDC lineage and therefore provide a framework for further studies aimed at more directly altering such cell-fate decisions for therapeutic exploitation of DC subsets.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: + of the supernatants were subjected to SDS-PAGE using NuPAGE 10% Bis-Tris gels (Invitrogen), transferred onto a nitrocellulose membrane sign a Transblot Turbo RTA Transfer Kit (Biorad), blocked in milk powder, and membranes were probed for anti-DC-SCRIPT (R&D Systems), anti-IRF8 and anti-ACTIN (Santa Cruz Biotechnology).
RT-PCR
RNAs were isolated using RNeasy Plus Mini Kit and cDNAs were synthesized from total RNAs using the iScript reverse transcription supermix for RT-QPCR (Biorad) according manufacturer's instructions. Amplification was performed with 2x Sensifast SYBR No ROX mix (Bioline) on a Biorad CFX 384 real-time PCR machine. Primers are described in Table S7 .
Zfp366 cloning
Full length coding sequence of flanked by Xho1 sites of Zfp366 was amplified from cDNA generated from RNA isolated from wt splenic cDC. Primers are listed on the Key Resources Table. cDNA was cloned into TOPO-TA cloning kit (Invitrogen) according to the manufacturer's recommendations. DC-SCRIPT cDNA was subsequently subcloned into pMSCV-iresGFP upstream of the IRES-GFP reporter gene.
Retroviral transduction
Retroviral supernatants were generated by transient transfection of 293T cells with plasmids encoding viral envelope proteins (pMD1-gag-pol and pCAG-Eco), and expression vectors encoding for pMSCV-iresGFP and pMSCV-Zfp366iresGFP using FuGeneHD (Promega). Retroviral supernatants were centrifuged onto RetroNectin (Takara)-coated plates for 45 min at 4000 rpm at 4 C. Cells were then cultivated with the virus in the presence of 4 mg/ml polybrene (Sigma-Aldrich) for 12 hr.
Guide RNA design and lentivirus production sgRNA constructs were introduced into the previously described pFH1tUTG (Aubrey et al., 2015) . sgRNA design was performed using the MIT CRISPR design software (http://crispr.mit.edu). To clone the individual sgRNA, 24bp oligonucleotides containing the sgRNA sequence was synthesized (sgIrf8: 5 0 -tcccAGTTTACCGAATTGTCCCCG-3 0 5 0 -aaacCGGGGACAATTCGGTAAACT-3 0 sgZfp366: 5 0 -tcccTACAGCCCGAGGCTTCCCGA-3 0 5 0 -aaacTCGGGAAGCCTCGGGCTGTA-3 0 ). A 4bp overhang for the forward (TCCC) and complementary reverse (AAAC) oligonucleotides enabled cloning into the BsmbI site of the lentivirus construct. Lentivirus production was described elsewhere (Aubrey et al., 2015) .
Lentiviral transduction of progenitor cells
Bone marrow was isolated from C57BL/6-Ly5.1 and Cas9Tg GFP (Ly5.2) mice. Hematopoietic progenitors were enriched using anti-CD117 magentic beads (Miltenyi). Positively selected progenitors cells were subsequently sorted by flow cytometry as Lin /100 mL StemSpan (StemCell Technologies), supplemented with 50 ng/ml mSCF (in house). Progenitors were co-cultured in presence of 20ul of 100x concentrated lentivirus (100,000 MWCO Amicon columns (Millipore)) encoding for either Irf8 (sgIrf8) or Zfp366 (sgZfp366) guide RNA, and were centrifuged at 900 g for 90 min at room temperature. The next day, cells were washed and added to each well. Plates were spun at 900 g for 90 min at room temperature, then cultured at 37 C with 5% CO 2 -in-air overnight. Cells were collected the next day and adoptively transferred intravenously into sub-lethally irradiated C57BL/6 x C57BL/6-Ly5-1 F1 hosts (3x10 4 cells from each genotype).
QUANTIFICATION AND STATISTICAL ANALYSIS
The statistical significance of non-RNA-seq data was assessed with Prism 7 software (GraphPad). Student's t tests for all single comparisons were two-tailed and unpaired and assumed Gaussian distribution and equivalent standard deviation. Enrichment of PU.1 activated genes in the cDC1 and cDC2 signatures was examined using a Fisher's exact test. Bar graphs display the mean ± SD. Description of the statistical tests can be found in the figure legends. p values < 0.05 were considered significant.
DATA AND SOFTWARE AVAILABILITY
RNA-seq and ChIP-seq raw data and read counts are available from the GEO repository as series GEO: GSE121446 (RNA-seq) and GEO: GSE121544 (ChIP-seq).
